Latest Regulatory Decisions News

The Takeovers Panel has declined Atlas Arteria’s bid to block Diamond Infraco from dispatching its takeover Bidder’s Statement, prolonging uncertainty over the contested offer.

Clarity Pharmaceuticals has secured a major manufacturing deal with Nucleus RadioPharma to produce its next-generation prostate cancer imaging agent, 64Cu-SAR-bisPSMA, ramping up supply ahead of anticipated US market entry.

Manuka Resources’ subsidiary Trans-Tasman Resources has received a draft decision proposing to decline consent for its Taranaki VTM iron sands project, challenging the company’s plans to develop a critical minerals supply in New Zealand.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Pancontinental Energy has identified two new prospects in its PEL 87 permit, boosting its high case prospective resources to 6.1 billion barrels of oil net to the company. While progressing farmout discussions, the company awaits a critical permit extension decision from Namibian authorities.

Lumos Diagnostics reported a strong surge in FebriDx® sales alongside positive FDA feedback, securing full Medicare reimbursement and advancing key clinical studies.

MyEco Group Ltd has reported record quarterly sales of its MyEcoBag® products, alongside improved gross margins and a significant reduction in operating cash outflows following a strategic operational restructure.

Berkeley Energia reports promising metallurgical results from its Conchas critical minerals project in Spain while pursuing a US$1 billion arbitration over permitting delays at its Salamanca uranium project.

The Takeovers Panel has declined to investigate allegations of undisclosed shareholder associations at Cyclone Metals, following a contentious director removal. This decision signals regulatory confidence in the company’s governance stability.

Manuka Resources is gearing up to recommence gold and silver production in the Cobar Basin by mid-2026 while awaiting a pivotal regulatory decision on its large-scale iron sands project in New Zealand.

Immutep Limited reports robust progress in its pivotal Phase III TACTI-004 trial for advanced non-small cell lung cancer, with over 120 clinical sites activated across 27 countries including the US. Patient enrolment has reached 38% of the target, keeping key milestones on track.

The Takeovers Panel has declined to find unacceptable circumstances in Emu NL’s recent placement before its AGM, ruling no control effect was evident. This decision underscores regulatory caution around capital raises near board votes.